Company Description
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases.
The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Randy Milby |
Contact Details
Address: 1200 Route 22 East, Suite 2000 Bridgewater, New Jersey 08807 United States | |
| Phone | 908 955 3140 |
| Website | tharimmune.com |
Stock Details
| Ticker Symbol | THAR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001861657 |
| ISIN Number | US4327052001 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Randy Milby | Chief Executive Officer |
| Thomas Hess | Chief Financial Officer |
| Sireesh Appajosyula | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | EFFECT | Notice of Effectiveness |
| Dec 19, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 17, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Jul 23, 2024 | 424B3 | Prospectus |